Sunshine Biopharma Q1 revenue up 18% to $8.9M; net loss narrows

Sunshine Biopharma Inc.

2025-Q1 EPS reported -$0.44 revenue$8,901,341

Revenue of $8.9 million in Q1 2025, up 18% from $7.5M in Q1 2024.
Net loss improved to $1.18M from $1.28M in prior-year quarter.
Appointed Michel Roy as new Chief Commercial Officer.
Launched 6 new generic drugs: two antibiotics, two GI drugs, two schizophrenia drugs.
Completed preclinical studies confirming K1.1 mRNA-LNP activity against hepatocellular carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.